204 related articles for article (PubMed ID: 18516780)
1. [Clinical experience in the treatment of neovascular age-related macular degeneration with pegaptanib].
Maier M; Feucht N; Huebner M; Lohmann C
Klin Monbl Augenheilkd; 2008 Jun; 225(6):582-7. PubMed ID: 18516780
[TBL] [Abstract][Full Text] [Related]
2. [Clinical experience with pegaptanib in the treatment of age-related macular degeneration (AMD)].
Thelen U
Klin Monbl Augenheilkd; 2010 Jan; 227(1):67-72. PubMed ID: 19842076
[TBL] [Abstract][Full Text] [Related]
3. Treatment of naïve lesions in neovascular age-related macular degeneration with pegaptanib.
Quiram PA; Hassan TS; Williams GA
Retina; 2007 Sep; 27(7):851-6. PubMed ID: 17891008
[TBL] [Abstract][Full Text] [Related]
4. Progression of choroidal neovascularization following injection of pegaptanib sodium (macugen) in two eyes with neovascular age-related macular degeneration.
Williams AJ; Fekrat S
Am J Ophthalmol; 2006 Oct; 142(4):683-4. PubMed ID: 17011868
[TBL] [Abstract][Full Text] [Related]
5. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.
; D'Amico DJ; Masonson HN; Patel M; Adamis AP; Cunningham ET; Guyer DR; Katz B
Ophthalmology; 2006 Jun; 113(6):992-1001.e6. PubMed ID: 16647134
[TBL] [Abstract][Full Text] [Related]
6. RPE tears after pegaptanib treatment in age-related macular degeneration.
Chang LK; Flaxel CJ; Lauer AK; Sarraf D
Retina; 2007 Sep; 27(7):857-63. PubMed ID: 17891009
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
8. Pegaptanib sodium treatment in neovascular age-related macular degeneration: clinical experience in Germany.
Feucht N; Matthias H; Lohmann CP; Maier M
Clin Ophthalmol; 2008 Jun; 2(2):253-9. PubMed ID: 19668713
[TBL] [Abstract][Full Text] [Related]
9. Pegaptanib: choroidal neovascularization in patients with age-related macular degeneration and previous arterial thromboembolic events.
Battaglia Parodi M; Di Bartolo E; Brue C; Cappello E; Furino C; Giuffrida S; Imparato M; Reibaldi M
Eur J Ophthalmol; 2018 Jan; 28(1):58-62. PubMed ID: 29077191
[TBL] [Abstract][Full Text] [Related]
10. [Intravitreal injection of bevacizumab for exsudative AMD with occult or minimal classic choroidal neovascularisation (CNV)].
Maier M; Feucht N; Haas K; Fiore B; Winkler von Mohrenfels C; Clos A; Lohmann C
Klin Monbl Augenheilkd; 2008 Sep; 225(9):818-24. PubMed ID: 18759214
[TBL] [Abstract][Full Text] [Related]
11. Pegaptanib for neovascular age-related macular degeneration.
Gragoudas ES; Adamis AP; Cunningham ET; Feinsod M; Guyer DR;
N Engl J Med; 2004 Dec; 351(27):2805-16. PubMed ID: 15625332
[TBL] [Abstract][Full Text] [Related]
12. Quantitative comparison of optical coherence tomography after pegaptanib or bevacizumab in neovascular age-related macular degeneration.
Joeres S; Kaplowitz K; Brubaker JW; Updike PG; Collins AT; Walsh AC; Romano PW; Sadda SR
Ophthalmology; 2008 Feb; 115(2):347-354.e2. PubMed ID: 17628685
[TBL] [Abstract][Full Text] [Related]
13. [Intravitreal bevacizumab (Avastin) iniections for neovascular age-related macular degeneration (AMD)--preliminary results].
Mackiewicz J; Mańkowska A; Dolar-Szczasny J; Zubilewicz A; Oleszczuk A; Nowomiejska K; Rejdak R; Zagórski Z
Klin Oczna; 2007; 109(4-6):146-9. PubMed ID: 17725273
[TBL] [Abstract][Full Text] [Related]
14. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Fung AE; Lalwani GA; Rosenfeld PJ; Dubovy SR; Michels S; Feuer WJ; Puliafito CA; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration.
Emerson MV; Lauer AK; Flaxel CJ; Wilson DJ; Francis PJ; Stout JT; Emerson GG; Schlesinger TK; Nolte SK; Klein ML
Retina; 2007; 27(4):439-44. PubMed ID: 17420695
[TBL] [Abstract][Full Text] [Related]
16. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
Kaiser PK; Blodi BA; Shapiro H; Acharya NR;
Ophthalmology; 2007 Oct; 114(10):1868-75. PubMed ID: 17628683
[TBL] [Abstract][Full Text] [Related]
17. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration.
Yoganathan P; Deramo VA; Lai JC; Tibrewala RK; Fastenberg DM
Retina; 2006; 26(9):994-8. PubMed ID: 17151485
[TBL] [Abstract][Full Text] [Related]
18. Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration.
Gupta B; Adewoyin T; Patel SK; Sivaprasad S
Br J Ophthalmol; 2011 Mar; 95(3):386-90. PubMed ID: 20693484
[TBL] [Abstract][Full Text] [Related]
19. Aqueous vascular endothelial growth factor after intravitreal injection of pegaptanib or ranibizumab in patients with age-related macular degeneration.
Sawada O; Miyake T; Kakinoki M; Sawada T; Kawamura H; Ohji M
Retina; 2010; 30(7):1034-8. PubMed ID: 20616682
[TBL] [Abstract][Full Text] [Related]
20. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results.
Leydolt C; Michels S; Prager F; Garhoefer G; Georgopoulos M; Polak K; Schmidt-Erfurth U
Acta Ophthalmol; 2010 Aug; 88(5):594-600. PubMed ID: 19485959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
